All In Biotech

Drug Trial Radar · NCT07108153

Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

A Phase 2a Randomized, Double-blind, Placebo-controlled Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Physician-prescribed Trikafta® in People With Cystic Fibrosis Who Are Homozygous for the F508del Mutation

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Nov 3, 2025

Primary completion

Jun 25, 2026

Study completion Jun 25, 2026

Sponsor

Lead sponsor
Sionna Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Aug 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta.

Conditions

  • Cystic Fibrosis (CF)

Interventions

  • SION-719Drug

    All participants receive SION-719, as specified by their treatment sequence assignment

  • Placebo-to-match SION-719Drug

    All participants receive placebo to match SION-719, as specified by their treatment sequence assignment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] when SION-719 is administered to people with cystic fibrosis (CF) who are taking a standard stable dose of physician-prescribed TrikaftaTime frame: Day 1 through day 57

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • National Jewish Health

    Denver, Colorado

  • University of Iowa

    Iowa City, Iowa

  • Johns Hopkins

    Baltimore, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • Washington University

    St Louis, Missouri

  • New York Medical College

    Hawthorne, New York

  • Columbia University

    New York, New York

  • University Hospital of Cleveland

    Cleveland, Ohio

  • Medical University of South Carolina

    Charleston, South Carolina

  • University of Washington

    Seattle, Washington

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Gold Coast University Hospital

    Southport, Queensland, Australia

  • Monash University

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.